Progress report on the stimulant-depressant abuse liability evaluation project.
The laboratories reported data on CPDD 1 that was indeed very similar to that of their direct or historical controls for diazepam. It is clear that the antagonists used in the program will reverse only a benzodiazepine-induced behavioral effect. The data on bromazepam suggest a very similar pattern and potency for this benzodiazepine compared to diazepam.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000633:toxicity; D001143:Arousal / Q000187:drug effects; D001960:Bromazepam / Q000633:toxicity; D003975:Diazepam / Q000633:toxicity; D004193:Discrimination Learning / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D009048:Motor Skills / Q000187:drug effects; D019966:Substance-Related Disorders / Q000523:psychology*
D014151:Anti-Anxiety Agents; D003975:Diazepam; D001960:Bromazepam